Although there was no statistically proven association between PARP1 expression and IDH mutation status, a recent study reported that 2-hydroxyglutarate produced by mutated IDH induces PARP inhibitor sensitivity in patient-derived primary glioma cells and genetically matched tumour xenografts [28], which has therapeutic implications. The gene discussed is PARP1; the disease is central nervous system cancer.